Moberg Pharma AB (Formerly known as Moberg Derma) And Menarini Group Extend Distribution Agreement For Kerasal Nail To South East Asia

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SINGAPORE--(BUSINESS WIRE)--Moberg Pharma AB (OMX: MOB) and Menarini Asia-Pacific, a member of the Menarini Group are pleased to announce that Menarini Asia-Pacific has been granted the exclusive rights to market and sell Kerasal Nail™ in eight Southeast Asian countries. The extended distribution agreement builds on an existing collaboration between the two company groups, which resulted in a successful launch of the product in Italy and a previous extension of the distribution agreement for China. In Asia-Pacific, Menarini is a leading regional biopharmaceutical company with over 3500 employees in 13 markets and a strong track record in launching and promoting Consumer Health brands. The global sales of the Menarini Group exceed 3 billion Euros.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC